Friday, 03 Apr 2020

You are here

Gout is Undermanaged

Gout should be one of the easiest and best managed of rheumatic disorders.  However, numerous deficits exist with regard to the treatment and long-term care of gout.

Swedish investigators have assessed the likelihood of gout patients that would receive and persist with urate lowering therapy.

Using a population-based cohort of 7709 incident gout patients from western Sweden they found that within the first year of their gout diagnosis, 32% received ULT.  Higher rates of ULT were seen in males, and those patients with diabetes, cardiovascular and renal disease.

However, a majority (75%) did not persist with ULT treatment within the first 2 years. Age <50 years, lack of comorbidities, and “normal kidney function” or “end-stage kidney failure” were associated with non-persistence with ULT.

Only a minority of patients received ULT and a majority of these did not persist with treatment over the next 2 years.  Persistent therapy was more likely in older patients and those with renal impairment and comorbidities.

Although there was no control group or "gold standard" for persistence, it seems obvious that those who need ULT, should remain on ULT.

Gout continues to be undermanaged by those who believe they can manage gout. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.